Sarah K Tasian, MD

faculty photo
Assistant Professor of Pediatrics at the Children's Hospital of Philadelphia
Department: Pediatrics

Contact information
Division of Oncology
Hematologic Malignancies section
3501 Civic Center Boulevard, CTRB 3010
Philadelphia, PA 19104
Office: 215.590.5476 admin
BS, BA (Biological Sciences, Psychology)
University of Notre Dame, 1999.
MD (Medicine)
Baylor College of Medicine, 2004.
(Pediatrics Residency)
Seattle Children's Hospital and University of Washington, 2007.
(Pediatric Hematology-Oncology Fellowship)
University of California, San Francisco (UCSF), 2011.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

I have clinical expertise in the care of children, adolescents, and young adults with hematologic malignancies, particularly those with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and juvenile myelomonocytic leukemia (JMML). My particular clinical interests include integration of genomic data with therapy for children with high risk newly-diagnosed and relapsed ALL and AML with a focus on precision medicine treatment approaches.

I attend on the Hematologic Malignancies inpatient service and outpatient Oncology clinic at the Children's Hospital of Philadelphia. I have procedural expertise in lumbar punctures, Ommaya reservoir taps, administration of intrathecal chemotherapy, and bone marrow aspiration and biopsy.

Description of Other Expertise

I am a primary clinical mentor in Hematologic Malignancies for first, second, and third year pediatric hematology-oncology fellows and supervise their patient care in the inpatient and outpatient clinical settings.

Description of Research Expertise

My career goal as an academic physician-scientist is to develop molecularly-targeted therapies for children with high-risk leukemias to prevent relapse, improve survival, and minimize toxicities.

My independent translational research program focuses upon novel therapeutics for high-risk pediatric leukemias via:
(1) Characterization of signal transduction networks and preclinical testing of kinase inhibitors for subtypes of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)
(2) Preclinical testing of leukemia antigen-redirected chimeric antigen receptor (CAR) T cell immunotherapy for childhood AML
(3) Early phase clinical trial testing of targeted therapies for children with leukemia through the Children’s Oncology Group (COG) and other consortia

Successful integration of our bench-based and clinical studies has led to several clinical trials testing novel therapies in children with high-risk leukemias. I have leadership roles in the COG ALL and AML disease committees and am the COG Developmental Therapeutics Vice Chair of Biology for Hematologic Malignancies. I also chair the COG AALL1521 phase 2 trial testing the efficacy of ruxolitinib in children with JAK pathway-mutant Ph-like ALL and am involved in development of early phase trials of CAR T cell immunotherapy for patients with relapsed/refractory AML at CHOP and Penn. I am also the co-principal investigator of the Center for Childhood Cancer Research hematologic malignancies biorepository.

Selected Publications

Sexauer, AN; Tasian, SK: Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia. Front Pediatr. 5(248), Nov 2017.

Tasian SK, Loh ML, Hunger SP: Philadelphia chromosome-like acute lymphoblastic leukemia. Blood Oct 2017.

Maese L, Tasian SK, Raetz EA: How is the Ph-like signature being incorporated into ALL therapy? Best Practice & Research Clinical Haematology 30(3): 222-228, Sep 2017.

Yahiaoui A, Loftus JP, Axelrod M, Forslund A, Tannheimer S, Tasian SK: Preclinical Activity of Entospletinib in Childhood B-Cell Acute Lymphoblastic Leukemia. Haematologica Page: P1286, June 2017 Notes: Highlighted poster presentation at European Hematological Association annual meeting; Madrid, Spain.

Kruth KA, Fang M, Shelton DN, Abu-Halawa O, Mahling R, Yang H, Weissman JS, Loh ML, Müschen M, Tasian SK, Bassik MC, Kampmann M, Pufall MA: Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia. Blood 129(22): 3000-3008, Jun 2017.

Glisovic-Aplenc T, Gill S, Spruce LA, Smith IR, Fazelinia H, Shestova P, Ding H, Tasian SK, Aplenc R, Seeholzer SH: Improved surfaceome coverage with a label-free nonaffinity-purified workflow. Proteomics 17(7), Apr 2017.

Tasian Sarah K, Kenderian Saad S, Shen Feng, Ruella Marco, Shestova Olga, Kozlowski Miroslaw, Li Yong, Schrank-Hacker April, Morrissette Jennifer J D, Carroll Martin, June Carl H, Grupp Stephan A, Gill Saar: Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood 129(17): 2395-2407, Apr 2017.

Rheingold Susan R, Tasian Sarah K, Whitlock James A, Teachey David T, Borowitz Michael J, Liu Xiaowei, Minard Charles G, Fox Elizabeth, Weigel Brenda J, Blaney Susan M: A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114). British Journal of Haematology Mar 2017.

Tasian SK, Hunger SP: Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics. British Journal of Haematology 176(6): 867-882, Mar 2017.

Akgumus GT, Gallo DJ, Surrey LF, Aplenc R, Bagatell R, Bhatti T, Brodeur G Hunger SP, Luo M, Maris JM, Mosse Y, Santi-Vicini M, Tasian SK, Waanders SJ, Chang F, Zelley K, Li MM: Cancer Predisposition Identified in Tumor-Only Next Generation Sequencing: Experience from the Children's Hospital of Philadelphia. March 2017 Notes: Platform presentation at American College of Medical Genetics Annual Meeting; Phoenix, AZ - given by collaborator.

back to top
Last updated: 02/12/2018
The Trustees of the University of Pennsylvania